Tag: Alzheimer’s prevention

Posted on

Does Fish Oil Help Alzheimer’s? What Studies Show

The Fish Oil Paradox: Benefits, Risks, Evidence

The “Brain Insurance” Myth

If you walk into any health food store today, you’ll see aisles dedicated to Omega-3 supplements. They’re sold as ‘brain insurance’ — the idea that a few capsules a day can shield you from Alzheimer’s, or other forms of cognitive decline and dementia.

It’s a multi-billion-dollar industry built on a foundation of some admittedly promising science. But lately, the narrative has started to shift. We’re seeing large-scale meta-analyses that don’t quite back up the hype. “Meta-analyses” are large studies that combine many clinical trials.

 A few recent studies suggest we might actually be taking risks that we didn’t “sign up” for.

Today, I want to walk through some of the actual data — looking at four major clinical reviews, and one specific warning — to get a better handle on whether fish oil is actually protecting our brains, or if you’re just wasting our money on (potentially rancid) piscine oil.

This isn’t medical advice — just a look at what the current evidence actually says. 

The Core Theory: Why We Care About DHA

To understand why we’re even talking about this, we have to look at what your brain is made of. 

About 60% of your gray matter is fat — by dry weight. And a huge portion of that is a specific Omega-3 fatty acid called docosahexaenoic (/duh-KOH-suh hek-suh-NOH-ick/) acid, or “DHA.”

Think of DHA as a key structural and functional component of neuronal membranes.

According to a 2018 update on Omega-3s and Alzheimer’s [Source 3], these fats do two main things. 

Firstly, they keep your cell membranes fluid. These membranes have to be flexible to stay functional when it comes to immune response, nerve signaling, and nutrient transport. 

And, secondly, DHA fats act as powerful anti-inflammatories.

Early on, Alzheimer’s is often described as ‘low-grade’ inflammation — like a fire smoldering under the surface. But over time, that can escalate into something sustained and destructive that doesn’t fully resolve..

On paper, Omega-3s should help calm that process.

And, in laboratory and animal studies, Omega-3 has been shown to reduce amyloid-beta accumulation — the plaques long considered hallmarks of the disease.

Though, as we’ll explore in a future video, it’s worth noting that the amyloid hypothesis itself has taken some serious hits recently, including high-profile controversies over foundational research. The science isn’t as settled as supplement labels would have you believe.

And, as we’ve learned in medicine, what happens in a petri dish doesn’t always happen in a human being. Indeed, the “low-grade” label is increasingly being considered an oversimplification.

That said, none of this has stopped supplement suppliers from making promises about fish oil — promises that, as we’ll see, the clinical data doesn’t fully back up.

The Reality Check: What the Data Says

This is where the “matter-of-fact” reality hits. I looked at a systematic review of over a dozen clinical trials [Source 1] and a landmark PubMed review [Source 2] to see if fish-oil supplements actually halt the sort of brain inflammation that develops into full-blown dementia.

Here is the honest breakdown.

If you have, or your loved one has, already gotten a diagnosis of Alzheimer’s Disease, then the supplements don’t seem to do much. The data shows no significant reversal of cognitive decline once the disease is established.

However — and this is a big “however” — some researchers have identified what they call a “window of opportunity.” The stronger evidence points to earlier intervention — pre-clinical stages, or mild cognitive impairment — not after diagnosis.

We’re talking about people with Mild Cognitive Impairment (“MCI”) or people who are cognitively healthy but have a genetic risk, like the APOE4 gene — a genetic variant linked to higher Alzheimer’s risk — which we have gotten into in a previous video.

So, if you’re waiting for memory loss to start before you take your brain health seriously, you’ve likely missed the boat for Omega-3s to be effective. 

If it’s anything, it’s better thought of as a preventative tool, not a rescue medication.

And even in studies that do show benefits, the effects tend to be modest — not dramatic. 

The Metric: “Test, Don’t Guess”

One of the biggest reasons people see mixed results is that they aren’t actually measuring if the supplement is working. A paper in the journal American Journal of Clinical Nutrition [Source 4] argues that we should be focusing on something called the Omega-3 Index.

Most people just take a pill and hope for the best. But everyone absorbs fats differently. The Omega-3 Index is a blood test. It measures how much EPA and DHA are actually built into your red blood cells — which reflects long-term intake. 

An index of ~8% or higher is the established cardiovascular target; brain health research is pointing in the same direction, though that threshold isn’t yet definitive.

If you’re taking a low-quality supplement or your body isn’t absorbing it well, you might still be at a 4% or 5% index — which is basically a deficiency zone.

If you aren’t testing your levels, you’re essentially flying blind. You might be taking a dose that’s too low to matter, or wasting money on a supplement your body isn’t even processing.

You can’t improve what you don’t track.

The Potential Problem: Oxidation and AFib

Now, we should address the “red flag” that’s been popping up in recent headlines. 

A report from SciTechDaily [Source 5] highlighted a potential risk that many supplement companies don’t want to talk about: Oxidation.

Fish oil can be unstable. There’s concern that poorly stored or low-quality fish oil may oxidize  or, to put it more dramatically, the worry is that it could go rancid when exposed to heat, light, or air. 

Plainly, if it turned out that you were swallowing oxidized fish oil, then you wouldn’t be reducing inflammation — you’d potentially be introducing oxidative stress into your system.

But there’s a more specific medical concern. Recent data has linked high-dose fish oil supplementation to an increased risk of Atrial Fibrillation, or AFib — which is an irregular heart rhythm that can lead to strokes.

Now, I want to be careful with my language here, because this finding doesn’t quite fit the definition of an “outlier” that some have used to describe it. An outlier is a single anomalous data point. The AFib signal isn’t that — it has shown up across multiple large clinical trials, which actually makes it a replicated finding. That’s more serious, not less. The supplement industry might prefer you think of this as a fringe result. It isn’t.

This risk appears more pronounced at higher doses and in certain populations.

For example, in this case, the data suggests that “megadosing” fish oil — say, taking 4 or 5 grams a day without a doctor’s supervision — might be creating cardiovascular risks that outweigh the potential brain benefits, especially if you aren’t actually deficient to begin with. Which — again — you won’t know until your levels are measured.

And, to be fully transparent, some risk signals have appeared at lower doses too, particularly in prescription-grade formulations. 

The honest bottom line is that the dose threshold isn’t perfectly established yet. Which is all the more reason to loop in your doctor before you dramatically increase your intake.

So yes — there’s a real risk conversation to have here, particularly around dose. But risk in context isn’t the same as “don’t bother.” It just means: be deliberate.

Conclusion: The Pragmatic Approach

So where does that leave us?

Omega-3s clearly matter for brain structure — but supplements aren’t a magic solution.

If you’re thinking about using them, a more grounded approach looks like this:

First: prioritize food. Fatty fish like sardines, mackerel, and salmon provide Omega-3s in a more stable, nutrient-rich form.

Second: if you do supplement, be picky. Fish oil is fragile — and quality matters. Choose third-party tested products. Look for labels like the dedicated, so-called “International Fish Oil Standards” program, or “IFOS” (/EYE-fohs/). And… If it smells off, don’t use it.

And third: know your numbers. The Omega-3 Index can tell you whether you’re actually in an meaningful range — or just guessing.

Because in the end, brain health isn’t about one supplement. It’s about maintaining the integrity of your brain over decades.

Fish oil may be one tool — but it’s not the whole toolbox.

If you found this helpful, consider subscribing for future breakdowns like this. And feel free to share it with someone who might benefit.

And, as always, we wish you all the best with your Alzheimer’s-proofing journey. Thanks for watching.

Sources:

[1]: https://pubmed.ncbi.nlm.nih.gov/28986068/ “Effectiveness of omega-3 fatty acid supplementation in patients with Alzheimer disease: A systematic review and meta-analysis – PubMed”

[2]: https://pubmed.ncbi.nlm.nih.gov/19523795/ “Omega-3 fatty acids and dementia – PubMed”

[3]: https://pubmed.ncbi.nlm.nih.gov/30084334/ “A Recent Update on the Effects of Omega-3 Fatty Acids in Alzheimer’s Disease – PubMed”

[4]: https://pmc.ncbi.nlm.nih.gov/articles/PMC9761771/ “The omega-3 index in Alzheimer’s disease: Ready for prime time? – PMC”

[5]: https://scitechdaily.com/scientists-uncover-potential-brain-risks-of-popular-fish-oil-supplements/

Posted on

Nose-Picking Linked to Alzheimer’s?

Could Nose-Picking Raise Alzheimer’s Risk?

Introduction: Surprising Links

Given the research we do for this channel, I am no stranger to surprising, sometimes controversial—and occasionally disgusting—claims regarding Alzheimer’s disease.

In a previous video, we explored how something as mundane as earwax buildup—or, more technically, cerumen impaction—could lead to hearing loss and, by extension, cognitive decline.

Today, we’re looking at a physical habit.

It’s often dismissed as a minor social faux pas—and was even the subject of jokes in an old Seinfeld episode. But recent research suggests this common behavior might create a pathway for certain pathogens to reach the brain.

We’re talking about nose-picking—and its potential link to late-onset dementia.

For the companion video, see here:

The Griffith University Study

A team of researchers at Griffith University in Australia published a 2022 study in the journal Scientific Reports. They focused on a bacterium called Chlamydia pneumoniae.

This common airborne bacterium—sometimes called the Taiwan Acute Respiratory Agent—is primarily known for causing bronchitis and pneumonia. However, it has also been detected in a significant number of human brains affected by late-onset dementia.

Using mouse models, the researchers tracked how this bacterium travels. What they found was striking: it can move along the olfactory nerve—from the nasal cavity directly into the brain.

In these models, infection reached the central nervous system within 24 to 72 hours. Once inside, it triggered amyloid-beta deposition—the same protein associated with Alzheimer’s plaques.

One interpretation is that amyloid-beta may function as part of the brain’s immune response to infection. However, if that infection becomes chronic or repeatedly facilitated—potentially through damage to the nasal lining—this process could contribute to neurodegeneration.

In short: this research suggests that certain behaviors might make it easier for pathogens to access the brain.

Connection: The Earwax Analogy

You may remember from our earwax discussion that conductive hearing loss involves a physical obstruction—something like earwax blocking sound transmission.

In a similar way, the nasal epithelium acts as both a physical and immunological barrier.

The Griffith University study found that when this barrier was damaged, infections in the mice became significantly more severe.

Think of the nasal lining as a security checkpoint: if it’s intact, most threats are stopped. If it’s compromised, things can slip through.

Just as we cautioned against inserting objects into the ear canal, scientists now warn that picking—or plucking nose hairs—can damage this delicate lining. That damage may give pathogens a clearer route to the brain.

Why This Matters

As geriatrician Maria Carney noted in our earwax discussion, “most people don’t even realize that they have an issue.”

That lack of awareness is a recurring theme in both Alzheimer’s prevention and detection.

While nose-picking is often associated with children, it remains common in adults. In fact, one study found that about 91% of people admit to it.

I’m curious how that compares with this audience—so I’ve put up an anonymous poll if you’d like to weigh in.

As many viewers know, age alone—especially over 65—significantly increases Alzheimer’s risk.

If we add environmental exposures, such as introducing pathogens through repeated nasal damage, this could represent an additional, potentially modifiable risk factor.

Caveats and Disclaimers

To be clear: this is early-stage research conducted in mice. We do not yet have direct evidence that this pathway operates the same way in humans.

Human trials would be needed to confirm whether a similar mechanism is at work.

And of course, Alzheimer’s disease likely involves multiple contributing factors—including acetylcholine loss, plaque formation through other mechanisms, neurofibrillary tangles, and nutritional or metabolic influences.

So yes—this hypothesis may sound farfetched.

But it is being seriously explored, and it may be worth paying attention to.

Practical Advice and Conclusion

One of the core goals of the Alzheimer’s Proof project is prevention. And unfortunately, there is no single solution—no magic bullet.

What we can do is try to stack the odds in our favor.

Protect the Barrier

Avoid plucking nose hairs and minimize behaviors that could damage the nasal lining. Chronic irritation may increase vulnerability.

Use Safer Alternatives

If needed, consider electric trimmers for grooming. For congestion, saline sprays or nasal irrigation may help. If using a neti pot, always use distilled or properly purified water.

Keep It Clean

If you must manually clear your nose, ensure your hands are clean—before and after. Also keep fingernails trimmed and smooth to reduce the risk of micro-injury.

Stay Aware

Consult a healthcare provider if you experience persistent irritation, bleeding, or signs of infection.

The key takeaway here isn’t panic—it’s awareness.

Small habits, repeated over time, can shape long-term brain health.

And if reducing Alzheimer’s risk comes down—even in part—to eliminating preventable factors, then even small changes may be worth considering.

________________________________________

References:

Posted on

CBD, Brain Inflammation, and a New Alzheimer’s Model

CBD and Dementia Inflammation

For decades, Alzheimer’s research has chased the same target — plaques and tangles.

And despite billions of dollars… results have been limited and often disappointing.

But… what if we’ve been aiming at the wrong problem entirely?

A new study suggests the real driver may be something more fundamental: inflammation.

And a compound called CBD might be able to dial it down.

Context: ‘Autoinflammatory’ Theory

To understand this breakthrough, we have to look at the “autoinflammatory” view of Alzheimer’s.

Traditionally, inflammation has been looked at as if it were a symptom of Alzheimer’s. But… researchers at Augusta University are arguing that chronic neuroinflammation is actually a core driver of the disease (along with other factors).

Translating that into dicey but everyday language, they’re starting to come around to the idea that inflammation is more of a contributing cause, not an effect.

Recall that, in general, “inflammation” is one of the body’s responses to illness or injury. In parts of our bodies we can see – an elbow, for instance (or…almost see!) – inflammation is what causes the hurt area to feel hot and painful, look red, swell in size, and so on.

Inflammation is often associated with loss of function. If your elbow is injured or inflamed, you can’t expect to be playing racquetball anytime soon.

Well… In Alzheimer’s disease, inflammation has to do with the brain’s immune system becoming chronically overactive. The brain gets stuck in a state of chronic immune activation. Yes, your brain can get inflamed, too.

This can also start a chemical chain reaction where usually functional neuronal “signals” begin to cause damage to nerve cells, instead of protecting them.

As a technical point, though, we don’t want to confuse inflammation (in the sense of haywire immune signaling and cellular activation) with what doctors call edema (i.e., large-scale fluid accumulation that increases pressure within the skull).

Think of it like this.

Your brain has a specialized immune system.

When it senses trouble, it sends out “first responders” like microglia and astrocytes.

In a healthy brain, these get to the scene of the accident, bandage the wounded, clean up, and go home.

But in Alzheimer’s, these cells get stuck in the “on” position. The emergency situation just goes on and on.

They stay “agitated,” and end up releasing toxic chemicals that (accidentally) kill the very neurons they were summoned to protect.

And this is where CBD enters the picture.

Science: IDO and cGAS

The study in question was led by Dr. Babak Baban. He and his team set out to see if cannabidiol, abbreviated “CBD,” could (so to speak) step into this mess as a peacekeeper.

CBD is already well known for its anti-inflammatory properties.

The researchers used a mouse model specially designed to mimic Alzheimer’s in humans.

They had these mice inhale CBD daily for four weeks. What they found wasn’t just “general” improvement. They identified two specific molecular “switches” that CBD was able to flip.

Two Molecular Switches

The first is an enzyme called IDO. It’s involved in how the brain processes tryptophan. You know, the essential amino acid that’s found in poultry – like your Thanksgiving turkey – which, by the way, has a largely undeserved “bad rep” for supposedly causing the “turkey coma” after you indulge. But that’s another story.

When overactive, IDO can shift tryptophan metabolism toward compounds that promote inflammation and neurotoxicity.

The second switch is a sensor called cGAS. This is basically a DNA-sensing pathway that can trigger powerful innate immune responses when activated.

In the Alzheimer’s-affected brains, both of these pathways were screaming at full volume.

But after the CBD treatment, the expression of IDO and cGAS dropped significantly.

Specifically, it quiets down the brain inflammation including in regions like the entorhinal cortex — a region critical for memory formation, and one of the first areas affected in Alzheimer’s.

By calming these two pathways, the CBD essentially told the brain’s immune system to “stand down.”

Results: Memory and Behavior

So, the biology changed, but did the behavior change? The symptoms?

Those are the “big” questions.

And the answer was… yes.

Remember, this is so far only demonstrated in animal studies. But…

The mice treated with CBD performed significantly better on recognition memory tests. And they showed more “exploratory behavior” than the untreated group. They weren’t just neurologically “calmer”; which researchers interpreted as improved cognitive function.

But here’s why this study is particularly exciting for the future of human medicine.

CBD appears to be a “multi-target” intervention.

While this specific study focused on inflammation, Dr. Baban’s team noted that their earlier work showed CBD may also influence plaque and tangle pathology through different mechanisms.

This is to say that, instead of a drug that only does one thing, we’re looking at a compound that might clear the trash, quiet the alarms, and protect the neurons all at the same time.

And notably, it’s derived from a plant.

Conclusion: The Road Ahead

Now. We have to be realistic.

This was only one study.

On mice.

While mouse models are essential for understanding these brain “switches” in a generic sense, humans — and our brains — are much more complex.

We still need rigorous human clinical trials to see if these results translate, what the right dosage is, and if long-term use is safe for seniors.

But…

If this line of research holds up, it changes the entire strategy.

Not just clearing damage — but preventing it at the source.

Not a single target — but an entire system reset.

And that raises a bigger question: Have we been looking for a silver bullet… when Alzheimer’s is really a systems-level failure?

If so, the future of treatment may not look like a drug that does one thing — but a therapy that brings the brain back into balance.

The question is: are we ready to rethink everything?

Including that an answer to one of our most complex diseases might be found in the chemistry of one of our most misunderstood plants.

What are your thoughts? Do you think the future of Alzheimer’s treatment lies in CBD, or are you still skeptical of cannabis-based medicine? Or are you more skeptical of pharmaceutical treatments? I’d love to read your comments.

By the way, if you’re interested in this idea of multi-target therapies, we’ve explored it before. In one video, we break down how CBD and THC interact with the brain.

And in another, we look at the controversial research into Lysergic acid diethylamide (or “LSD” and dementia — where, interestingly, a similar “systems-level” approach has been proposed. So if this direction intrigues you, those are worth watching next.

Posted on

Could a Common Sleep-Aid Drug Reduce Alzheimer’s Proteins?

Sleep-Drug May Reduce Dreaded Plaques and Tangles

What if a simple sleeping pill could help the brain wash away the very proteins linked to Alzheimer’s disease? A surprising new study suggests that an already FDA-approved insomnia medication may do exactly that.

Researchers have found that a common, Food-and-Drug-Administration-approved sleeping pill might actually reduce the buildup of toxic proteins linked to Alzheimer’s disease. 

Today, we’re diving into the reportage of the science behind this discovery. And we’ll discuss a bit about what it could mean for the future of dementia prevention.

The Study

First thing’s first: The study we’re concerned with was written up in an article titled “Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS,” which was published online in the March, 2023 edition of the scientific journal Annals of Neurology. And it was printed in a hard-copy version in July of the same year.

To understand the study, we first need to understand how the brain ‘cleans’ itself (quote, unquote) during sleep.  

While we sleep, our brain uses something called the “glymphatic system.” Think of it like a biological dishwasher. It flushes out metabolic waste that builds up while we’re awake.

Two of the most dangerous types of “trash” cleared out by this glymphatic system are amyloid-beta and tau proteins. 

Of course, viewers of this channel — not to mention anyone with a basic familiarity of Alzheimer’s — probably won’t fail to recognize these words.

After all, it’s these proteins that, when not cleared effectively, clump together into the notorious “plaques and tangles” that constitute the hallmarks of Alzheimer’s disease. 

This is one reason why chronic sleep deprivation is often cited as a major risk factor — alongside advanced age, of course — for cognitive decline.

Suvorexant

Enter a drug called suvorexant, known by the brand name “Belsomra.”

It’s a type of drug known as an “orexin-receptor antagonist.” Oversimplifying, orexin is a molecule in the brain that keeps us awake and alert. 

The idea is that, by blocking orexin, the drug suvorexant may encourage the brain to transition into sleep.

Researchers at Washington University School of Medicine in St. Louis, Missouri wanted to see if using this specific drug to “promote” or “enhance” sleep could help to lower the levels of the aforementioned toxic proteins.

To this end, and as scientific studies typically do, they took a group of thirty-eight healthy volunteers, aged 45 to 65, and gave them either a dose of suvorexant or a placebo before bedtime. Researchers then monitored the participants’ cerebrospinal fluid over the next 36 hours.

What Happened?

To hear them tell it, the results were striking. 

In the subset of participants who took the higher-than-usually-prescribed dose of suvorexant, levels of amyloid-beta dropped by 10 to 20 percent, compared to the placebo group. 

Even more significantly, the same group saw a drop in “phosphorylated tau” — a form of the tau protein that is particularly closely linked to brain-cell death and Alzheimer’s- disease progression.

What makes this exciting is that it wasn’t just “better sleep” clearing the brain (in some vague sense); it was a specific intervention that seemed to target the very precursors of Alzheimer’s pathology.

Caveats

However, before we get too ahead of ourselves, there are some major caveats. 

This was a very small study, and it only lasted for two nights. Therefore, researchers cannot yet say if taking this medication, long-term, will actually “prevent” dementia, or if the protein levels will stay low once the medication is stopped.

The researchers themselves prefer to refer to this as something more like a “proof-of-concept.” 

Of course, we would want to see much longer trials to decide if the observed reduction in proteins actually translates into a predictable — and reliable — reduction in cognitive decline.

That said, this study confirms that the intersection of sleep medicine and neurology is one of the most promising frontiers in medicine. And it suggests that we might eventually treat sleep not just as a lifestyle habit, but as a clinically significant tool that may help us to maintain brain health as we age.If you’re interested in the full details of the study, click for the ScienceAlert article or for the original paper. We hope you rest a little easier tonight!